| Autor: |
I. Juhan-Vague, C. Fossat, M. Bory, M. Lenoble, P. Bonitchi, M. David |
| Rok vydání: |
2015 |
| Předmět: |
|
| DOI: |
10.1159/000419690 |
| Popis: |
In experimental myocardial infarction, activated polymorphonuclears (PMN) have been shown to have a detrimental role in ischemic myocardial damage because of their progressive capillary plugging and their cytotoxic actions, such as production of free oxygen radicals and release of lysosomal enzymes. Thus, the extent of PMN activity may reflect the extent of ischemic myocardial injury and drugs able to reduce this PMN activation could be of clinical interest. The effect of pentoxifylline added to in vitro activated PMN has been studied and it has been observed that this drug could decrease the inflammatory response of neutrophils.Thus we found it interesting to study PMN activity in patients with acute myocardial infarction and the effect of in vitro addition of pentoxifylline on PMN functions.When studying PMN adherence, non directed and directed chemotaxis it was shown that leukocyte activation occuring in patients with myocardial infarction increased progressively after the event and was greater after 3 days (D3) than the morning after admission (D1).Pentoxifylline added in vitro was able to improve PMN functions when they were moderately altered that is at D1, and no effect could be demonstrated with intense activation (D3). Higher doses of pentoxifylline could have an effect in this case and have to be tested. Pentoxifylline could be useful in the treatment of patients with myocardial infarction by decreasing the PMN activation and therefore the myocardial injury. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
